Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
Authors
Keywords
-
Journal
Blood Advances
Volume 5, Issue 9, Pages 2438-2446
Publisher
American Society of Hematology
Online
2021-05-08
DOI
10.1182/bloodadvances.2020003895
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY
- (2020) Constantine S. Tam et al. BLOOD
- Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
- (2020) Steven P. Treon et al. JOURNAL OF CLINICAL ONCOLOGY
- Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
- (2020) Meletios Dimopoulos et al. Blood Advances
- How Recent Advances in Biology of Waldenström’s Macroglobulinemia May Affect Therapy Strategy
- (2019) Marine Baron et al. Current Oncology Reports
- New roles for B cell receptor associated kinases: when the B cell is not the target
- (2019) Phuong-Hien Nguyen et al. LEUKEMIA
- Importance of sequential analysis of TP 53 variation in patients with Waldenström Macroglobulinaemia
- (2019) Amy Christian et al. BRITISH JOURNAL OF HAEMATOLOGY
- CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib
- (2019) Jorge J. Castillo et al. BRITISH JOURNAL OF HAEMATOLOGY
- Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
- (2019) Roger G Owen et al. Lancet Haematology
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- TP53 mutations are associated with mutated MYD88 and CXCR4 , and confer an adverse outcome in Waldenström macroglobulinaemia
- (2018) Joshua N. Gustine et al. BRITISH JOURNAL OF HAEMATOLOGY
- Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia
- (2018) Marion Magierowicz et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
- (2018) Steven P. Treon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment
- (2017) A Paulus et al. Blood Cancer Journal
- Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity
- (2016) Jorge J. Castillo et al. LEUKEMIA & LYMPHOMA
- The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity inCXCR4Wild-typeandCXCR4WHIMmutated Waldenstrom macroglobulinaemia cells
- (2015) Yang Cao et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia
- (2015) M. F. M. de Rooij et al. HAEMATOLOGICA
- MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia
- (2015) M. F. M. de Rooij et al. HAEMATOLOGICA
- The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia
- (2014) Y Cao et al. LEUKEMIA
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
- (2013) G. Yang et al. BLOOD
- Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop
- (2012) Roger G. Owen et al. BRITISH JOURNAL OF HAEMATOLOGY
- MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
- (2012) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion
- (2010) Xiaoqun Sun et al. Contemporary Clinical Trials
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More